Gene therapy field discusses FDA shifts at Rome meeting

FDA leadership changes are a significant concern for the gene therapy field, even during European industry discussions. The departure of the FDA's top vaccine and gene therapy regulator was a key talking point at a recent Rome conference for cell and gene therapy makers. This highlights how US regulatory decisions heavily influence the global gene therapy landscape, impacting European market outlooks.